Edwards Lifesciences Corporation $EW Shares Acquired by Ballentine Partners LLC

Ballentine Partners LLC lifted its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,072 shares of the medical research company’s stock after purchasing an additional 963 shares during the period. Ballentine Partners LLC’s holdings in Edwards Lifesciences were worth $475,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its position in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after acquiring an additional 2,576,383 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Edwards Lifesciences by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after acquiring an additional 264,311 shares during the period. Nuveen LLC acquired a new position in Edwards Lifesciences in the 1st quarter valued at about $330,881,000. Invesco Ltd. increased its position in Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after acquiring an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Edwards Lifesciences by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after acquiring an additional 198,882 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on EW. Wells Fargo & Company boosted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Tuesday, July 29th. Truist Financial lifted their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Evercore ISI lifted their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the company an “in-line” rating in a report on Friday, July 25th. Finally, Mizuho boosted their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $86.61.

Insider Activity

In related news, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Up 1.4%

Shares of NYSE EW opened at $76.34 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average price of $78.50 and a 200 day moving average price of $75.72. The company has a market cap of $44.82 billion, a P/E ratio of 10.98, a P/E/G ratio of 3.67 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the company posted $0.70 EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.